DK3172202T3 - Heterocykliske carboxylsyrer som aktivatorer af opløselig guanylatcyclase - Google Patents

Heterocykliske carboxylsyrer som aktivatorer af opløselig guanylatcyclase Download PDF

Info

Publication number
DK3172202T3
DK3172202T3 DK15747311.7T DK15747311T DK3172202T3 DK 3172202 T3 DK3172202 T3 DK 3172202T3 DK 15747311 T DK15747311 T DK 15747311T DK 3172202 T3 DK3172202 T3 DK 3172202T3
Authority
DK
Denmark
Prior art keywords
activators
carboxylic acids
guanylate cyclase
soluble guanylate
heterocyclic carboxylic
Prior art date
Application number
DK15747311.7T
Other languages
Danish (da)
English (en)
Inventor
Jehrod Burnett Brenneman
Christopher Ronald Sarko
Zhonghua Zhang
Tamara Denise Hopkins
Michael D Lowe
Maolin Yu
John David Ginn
John Westbrook
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3172202(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK3172202T3 publication Critical patent/DK3172202T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
DK15747311.7T 2014-07-22 2015-07-21 Heterocykliske carboxylsyrer som aktivatorer af opløselig guanylatcyclase DK3172202T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462027376P 2014-07-22 2014-07-22
PCT/US2015/041245 WO2016014463A1 (en) 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Publications (1)

Publication Number Publication Date
DK3172202T3 true DK3172202T3 (da) 2020-04-27

Family

ID=53783363

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15747311.7T DK3172202T3 (da) 2014-07-22 2015-07-21 Heterocykliske carboxylsyrer som aktivatorer af opløselig guanylatcyclase

Country Status (26)

Country Link
US (1) US9353090B2 (enExample)
EP (1) EP3172202B1 (enExample)
JP (1) JP6602840B2 (enExample)
KR (1) KR20170035993A (enExample)
CN (1) CN106459017B (enExample)
AP (1) AP2016009615A0 (enExample)
AR (1) AR101265A1 (enExample)
AU (1) AU2015292833B2 (enExample)
BR (1) BR112017000943A2 (enExample)
CA (1) CA2955937A1 (enExample)
CL (1) CL2017000071A1 (enExample)
CO (1) CO2017000438A2 (enExample)
DK (1) DK3172202T3 (enExample)
EA (1) EA032972B1 (enExample)
ES (1) ES2784477T3 (enExample)
HU (1) HUE049231T2 (enExample)
IL (1) IL249587A0 (enExample)
MX (1) MX378717B (enExample)
PE (1) PE20170249A1 (enExample)
PH (1) PH12017500111A1 (enExample)
PL (1) PL3172202T3 (enExample)
PT (1) PT3172202T (enExample)
SG (2) SG11201700507XA (enExample)
TW (1) TWI711615B (enExample)
UY (1) UY36226A (enExample)
WO (1) WO2016014463A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697678A (zh) * 2016-02-01 2018-10-23 铁木医药有限公司 sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用
JP7058659B2 (ja) 2016-09-14 2022-04-22 ジェノマティカ， インコーポレイテッド １，３－脂肪ジオール化合物およびそれらの誘導体
WO2018069148A1 (de) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
CN106495999B (zh) * 2016-10-18 2019-08-16 亳州学院 一种芳香醛及其合成方法
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
BR112020000772A2 (pt) 2017-07-14 2020-07-21 Glaxosmithkline Intellectual Property Development Limited inibidores de cinase 2 de repetição rica em leucina
JP7461872B2 (ja) * 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EP3784238A4 (en) * 2018-04-27 2021-12-29 Hetero Labs Ltd. Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
US20210052528A1 (en) 2018-04-30 2021-02-25 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EP3793553A1 (en) 2018-05-15 2021-03-24 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
EA202191554A1 (ru) 2018-12-03 2021-09-02 Фмк Корпорейшн Способ получения n-фенилпиразол-1-карбоксамидов
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
IL299787A (en) 2020-07-16 2023-03-01 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
CN114957087A (zh) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德中间体制备方法
JP2025518350A (ja) 2022-06-09 2025-06-12 バイエル・アクチエンゲゼルシヤフト 女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026712A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. Quaternary amines and related inhibitors of factor xa
EP1906957A1 (en) 2005-07-18 2008-04-09 Bayer HealthCare AG Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
CA2686906A1 (en) 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators, sgc activators and combinations for the treatment of urological disorders
AU2008296974B2 (en) 2007-09-06 2013-10-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MX2010003071A (es) 2007-10-05 2010-04-01 Sanofi Aventis Deutschland Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor.
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
EP2264017A4 (en) 2008-04-04 2011-07-27 Takeda Pharmaceutical Heterocyclic derivative and its use
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
ES2493718T3 (es) 2009-01-17 2014-09-12 Bayer Intellectual Property Gmbh Estimuladores y activadores de sGC en combinación con inhibidores de PDE5 para el tratamiento de la disfunción eréctil
KR20110133034A (ko) 2009-02-26 2011-12-09 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
CN104800219A (zh) 2010-02-05 2015-07-29 阿德弗里奥药品有限责任公司 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
WO2013025425A1 (en) * 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
SG10201510668UA (en) 2012-09-07 2016-01-28 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma

Also Published As

Publication number Publication date
UY36226A (es) 2016-01-29
PH12017500111A1 (en) 2017-05-29
EP3172202A1 (en) 2017-05-31
AP2016009615A0 (en) 2016-12-31
CN106459017B (zh) 2020-07-17
PL3172202T3 (pl) 2020-07-13
EP3172202B1 (en) 2020-01-29
JP6602840B2 (ja) 2019-11-06
MX2017000926A (es) 2017-05-04
AR101265A1 (es) 2016-12-07
KR20170035993A (ko) 2017-03-31
AU2015292833B2 (en) 2019-11-28
PT3172202T (pt) 2020-05-06
CO2017000438A2 (es) 2017-08-31
BR112017000943A2 (pt) 2017-11-14
IL249587A0 (en) 2017-02-28
WO2016014463A1 (en) 2016-01-28
CN106459017A (zh) 2017-02-22
HUE049231T2 (hu) 2020-09-28
EA201790246A1 (ru) 2017-07-31
TW201617340A (zh) 2016-05-16
MX378717B (es) 2025-03-10
AU2015292833A1 (en) 2016-12-22
PE20170249A1 (es) 2017-04-05
JP2017521457A (ja) 2017-08-03
SG11201700507XA (en) 2017-02-27
US9353090B2 (en) 2016-05-31
TWI711615B (zh) 2020-12-01
EA032972B1 (ru) 2019-08-30
CL2017000071A1 (es) 2017-06-30
ES2784477T3 (es) 2020-09-28
CA2955937A1 (en) 2016-01-28
SG10201806565SA (en) 2018-08-30
US20160024059A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
DK3172202T3 (da) Heterocykliske carboxylsyrer som aktivatorer af opløselig guanylatcyclase
DK3447050T3 (da) Pyridin-2(1h)-on-quinolinderivater som mutant-isocitrat dehydrogenaseinhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
HUE057838T2 (hu) SHP2 inhibitorokként hasznos új heterociklusos származékok
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3356345T3 (da) Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
DK3293186T3 (da) Pyrimidinoner som faktor xia-hæmmere
EP3152214A4 (en) Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
DK3094631T4 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3348556T3 (da) Heteroarylamider som hæmmere af proteinaggregering
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK3166611T3 (da) Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer
DK3202766T3 (da) Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
DK3418273T3 (da) Derivater af flavagliner
IL249674A0 (en) Quinolizinone derivatives as pi3k inhibitors
DK3137658T3 (da) Anvendelse af kendte forbindelser som d-aminosyreoxidase-inhibitorer
DK3421458T3 (da) Benzo-fusionerede heterocykliske derivater som kan anvendes som agonister af gpr120
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
HUE042119T2 (hu) Aminoészter-származékok
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3138840T3 (da) Thiadiazolidin-derivat som anti-enterovirus 71
DK3280920T3 (da) Reversibel forbindelse af maskinkomponenter